Contact
searchSearch
HMP Global
Login

Opioid Use Disorder News

pills
News
Prevalence of Illicit Opioid Use Higher Than Previously Estimated
06/04/2025
Maria Mantas
The rate of illicit opioid use, including illicitly manufactured fentanyl (IMF) use, in adults aged 18 and older was higher than previously estimated, according to recent findings.
The rate of illicit opioid use, including illicitly manufactured fentanyl (IMF) use, in adults aged 18 and older was higher than previously estimated, according to recent findings.
The rate of illicit opioid use,...
06/04/2025
Psych Congress Network
woman practicing mindfulness
News
Mindfulness Training Restores Reward System Function, Reduces Cravings, in OUD
06/02/2025
Jolynn Tumolo
A mindfulness-based training intervention called Mindfulness-Oriented Recovery Enhancement (MORE) improved positive emotion regulation, and subsequently reduced opioid craving, in patients with opioid use disorder (OUD).
A mindfulness-based training intervention called Mindfulness-Oriented Recovery Enhancement (MORE) improved positive emotion regulation, and subsequently reduced opioid craving, in patients with opioid use disorder (OUD).
A mindfulness-based training...
06/02/2025
Psych Congress Network
doctor looks through medical records
News
Automated Technique Identifies Problematic Opioid Use From EHR Notes
05/05/2025
Jolynn Tumolo
A machine learning approach that automated the Addiction Behaviors Checklist identified problematic opioid use in patients with chronic pain by analyzing electronic health record (EHR) notes, according to a recent study.
A machine learning approach that automated the Addiction Behaviors Checklist identified problematic opioid use in patients with chronic pain by analyzing electronic health record (EHR) notes, according to a recent study.
A machine learning approach that...
05/05/2025
Psych Congress Network
patient taking pills
News
Low-Dose Buprenorphine Initiation May Prevent Opioid Withdrawal in Some Patients
04/28/2025
Jolynn Tumolo
Just 7% of patients who received low-dose buprenorphine initiation (LDBI) for opioid use disorder (OUD) experienced clinically significant opioid withdrawal, according to an updated systematic review.
Just 7% of patients who received low-dose buprenorphine initiation (LDBI) for opioid use disorder (OUD) experienced clinically significant opioid withdrawal, according to an updated systematic review.
Just 7% of patients who received...
04/28/2025
Psych Congress Network
an assortment of pills spilled out on a yellow table
News
Inpatient Addiction Consultation Service Promotes MOUD in Patients With OUD
04/14/2025
Jolynn Tumolo
According to randomized clinical trial findings, patients with opioid use disorder (OUD) who received inpatient addiction consultation service were more likely to initiate medication for OUD (MOUD) compared to those who received usual care.
According to randomized clinical trial findings, patients with opioid use disorder (OUD) who received inpatient addiction consultation service were more likely to initiate medication for OUD (MOUD) compared to those who received usual care.
According to randomized clinical...
04/14/2025
Psych Congress Network
open and spilled bottle of pills
News
US Drug Overdose Deaths Show Steep Decline in Most Recent Data
04/07/2025
Jolynn Tumolo
Drug overdose deaths dropped almost 24% in the US for the 12 months ending in September 2024 compared with the previous year, according to provisional data from the Centers for Disease Control and Prevention (CDC).
Drug overdose deaths dropped almost 24% in the US for the 12 months ending in September 2024 compared with the previous year, according to provisional data from the Centers for Disease Control and Prevention (CDC).
Drug overdose deaths dropped...
04/07/2025
Psych Congress Network
US FDA sign
News
FDA Seeks Clearer Labeling for Transmucosal Buprenorphine Product Dosing
03/24/2025
Jolynn Tumolo
To avoid misperceptions that current labeling for buprenorphine-containing transmucosal products includes a maximum daily dose, the US Food and Drug Administration (FDA) is encouraging the submission of supplemental new drug applications to...
To avoid misperceptions that current labeling for buprenorphine-containing transmucosal products includes a maximum daily dose, the US Food and Drug Administration (FDA) is encouraging the submission of supplemental new drug applications to...
To avoid misperceptions that...
03/24/2025
Psych Congress Network
emergency room hospital waiting room reception area
News
Why Aren’t More Emergency Departments Using Medications for OUD Treatment?
03/12/2025
Jolynn Tumolo
Barriers may be hampering the use of medications for opioid use disorder (MOUD) in US emergency departments (EDs), according to results from a systematic review published in the Journal of Substance Use & Addiction Treatment.
Barriers may be hampering the use of medications for opioid use disorder (MOUD) in US emergency departments (EDs), according to results from a systematic review published in the Journal of Substance Use & Addiction Treatment.
Barriers may be hampering the...
03/12/2025
Psych Congress Network
Opioid Use Disorder Incidence Declines After State Policy Limits Opioid Prescriptions
News
Opioid Use Disorder Incidence Declines After State Policy Limits Opioid Prescriptions
02/24/2025
Jolynn Tumolo
New diagnoses of opioid use disorder in Vermont steadily lessened, most noticeably in young adults, after the state limited opioid analgesic prescriptions for acute pain in 2017. Researchers reported their findings in the American Journal of...
New diagnoses of opioid use disorder in Vermont steadily lessened, most noticeably in young adults, after the state limited opioid analgesic prescriptions for acute pain in 2017. Researchers reported their findings in the American Journal of...
New diagnoses of opioid use...
02/24/2025
Psych Congress Network
Medication Use for OUD Low in Older Adults
News
Medication Use for OUD Low in Older Adults
02/19/2025
Evi Arthur
The rate of medication use for opioid use disorder (MOUD) was found to be low in older adults, according to a recent research brief published in the American Journal of Preventive Medicine. 
The rate of medication use for opioid use disorder (MOUD) was found to be low in older adults, according to a recent research brief published in the American Journal of Preventive Medicine. 
The rate of medication use for...
02/19/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use